| 000 | 01853 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250516124155.0 | ||
| 264 | 0 | _c20140930 | |
| 008 | 201409s 0 0 eng d | ||
| 022 | _a1433-8726 | ||
| 024 | 7 |
_a10.1007/s00345-012-1001-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTsao, Che-kai | |
| 245 | 0 | 0 |
_aCytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. _h[electronic resource] |
| 260 |
_bWorld journal of urology _cDec 2013 |
||
| 300 |
_a1535-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xtrends |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNephrectomy _xmethods |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aSEER Program _xstatistics & numerical data |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aSmall, Alexander C | |
| 700 | 1 | _aKates, Max | |
| 700 | 1 | _aMoshier, Erin L | |
| 700 | 1 | _aWisnivesky, Juan P | |
| 700 | 1 | _aGartrell, Benjamin A | |
| 700 | 1 | _aSonpavde, Guru | |
| 700 | 1 | _aGodbold, James H | |
| 700 | 1 | _aPalese, Michael A | |
| 700 | 1 | _aHall, Simon J | |
| 700 | 1 | _aOh, William K | |
| 700 | 1 | _aGalsky, Matthew D | |
| 773 | 0 |
_tWorld journal of urology _gvol. 31 _gno. 6 _gp. 1535-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00345-012-1001-3 _zAvailable from publisher's website |
| 999 |
_c22331215 _d22331215 |
||